Cancer Drugs Boost Bayer Despite Crop, Consumer and Currency Concerns
Executive Summary
The still pending acquisition of Monsanto, crop science problems in Brazil and a weak showing from consumer health in the US cannot disguise the strong growth that Bayer's pharmaceuticals business is continuing to enjoy.